Nasal Sprays Market Report 2026

The nasal sprays market size has grown rapidly in recent years. It will grow from $33.63 billion in 2025 to $37.24 billion in 2026 at a compound annual growth rate (CAGR) of 10.7%. The growth in the historic period can be attributed to increasing prevalence of nasal allergies, limited variety of nasal spray formulations, growing hospital and clinic visits, reliance on retail pharmacy distribution, awareness about nasal hygiene and respiratory care.

The nasal sprays market size is expected to see rapid growth in the next few years. It will grow to $55.37 billion in 2030 at a compound annual growth rate (CAGR) of 10.4%. The growth in the forecast period can be attributed to development of advanced steroid and antihistamine formulations, rise in home care treatment adoption, growth of e-pharmacy platforms, increasing vaccination programs via nasal sprays, introduction of combination and anticholinergic sprays. Major trends in the forecast period include rising demand for nasal sprays for allergic conditions, increased preference for over-the-counter (otc) products, expansion of online pharmacy distribution channels, growing use of nasal sprays in vaccination delivery, focus on formulation innovation and combination sprays.

The rising prevalence of respiratory disorders is anticipated to drive the growth of the nasal sprays market in the coming years. Respiratory disorders include chronic and acute conditions that impact the airways and lungs, such as asthma and chronic obstructive pulmonary disease. The occurrence of these conditions continues to increase due to population aging and ongoing exposure to both outdoor and indoor air pollutants. Nasal sprays address this growing demand by providing rapid and localized relief, enabling individuals to manage respiratory symptoms more effectively. For instance, in November 2024, according to the Australian Institute of Health and Welfare, an Australia-based government health agency, respiratory conditions accounted for 7.2% of the total disease burden in 2023, with chronic obstructive pulmonary disease (COPD) contributing 50% and asthma accounting for 35% of this burden. Therefore, the increasing prevalence of respiratory disorders is fueling the growth of the nasal sprays market.

Major companies operating in the nasal sprays market are emphasizing technological innovation, such as the development of next-generation nasal sprays, to deliver improved drug administration, enhanced bioavailability, and greater patient adherence. Next-generation nasal sprays utilize advanced formulations and delivery devices designed to ensure accurate dosing, better absorption, quicker onset of action, and improved user comfort compared to conventional nasal sprays. For example, in October 2023, Haleon Plc, a UK-based pharmaceutical company, introduced Otrivin Nasal Mist, a next-generation nasal spray created to enhance comfort and ease of use for individuals experiencing nasal congestion due to colds, allergies, or sinusitis. The product offers fast and effective congestion relief by constricting swollen blood vessels in the nasal passages, allowing easier breathing within minutes and providing relief for up to 12 hours. Its fine microdroplet mist and ergonomic design promote gentle, convenient use without irritation or dripping.

In January 2024, Kindeva Drug Delivery L.P., a US-based manufacturing company, acquired Summit Biosciences Inc. for an undisclosed amount. Through this acquisition, Kindeva Drug Delivery aims to expand its pharmaceutical portfolio and global leadership while adding specialized capabilities in nasal spray drug development and manufacturing. Summit Biosciences Inc. is a US-based pharmaceutical company specializing in the development, manufacturing, and commercialization of generic and innovative nasal spray products.

Major companies operating in the nasal sprays market are Pfizer Inc., Johnson & Johnson Services, Merck & Co. Inc., Bayer AG, AstraZeneca plc., Novartis AG, GlazoSmithKline plc, Viatris Inc., Teva Pharmaceutical Industries Ltd., Sandoz International GmbH, Catalent Inc., AptarGroup, Cipla Ltd, Emergent, Assertio Therapeutics Inc., Aytu BioPharma Inc., Leeford Healthcare Ltd, Ultratech India Limited, Aishwarya Group, Aurena Laboratories, Innovus Pharmaceuticals Inc.

North America was the largest region in the nasal sprays market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the nasal sprays market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the nasal sprays market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have affected the nasal sprays market by raising costs of imported active pharmaceutical ingredients (APIs) and spray devices, leading to increased production expenses. Segments like steroid and antihistamine nasal sprays are particularly impacted, with Asia-Pacific countries including India and China experiencing significant import duties. This has caused price fluctuations and supply chain delays. Positively, tariffs are encouraging local manufacturing, formulation innovation, and greater self-reliance in pharmaceutical production capacities.

The nasal sprays market research report is one of a series of new reports that provides nasal sprays market statistics, including nasal sprays industry global market size, regional shares, competitors with a nasal sprays market share, detailed nasal sprays market segments, market trends and opportunities, and any further data you may need to thrive in the nasal sprays industry. This nasal sprays market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Nasal sprays are liquid pharmaceutical formulations delivered through the nostrils using a spray mechanism. They offer localized treatment for conditions such as allergies, nasal congestion, and sinus infections by delivering medication directly to the nasal passages, enabling faster therapeutic action. These products are widely used because of their convenience and rapid effectiveness.

The product types of nasal sprays include steroid nasal sprays, antihistamine nasal sprays, decongestant nasal sprays, saline nasal sprays, and other variants. Steroid nasal sprays contain corticosteroids that help decrease inflammation within the nasal passages. These products are available as both over-the-counter and prescription medications. Distribution channels include retail pharmacies, hospital pharmacies, and online pharmacies. Applications of nasal sprays encompass nasal congestion, allergic and non-allergic rhinitis, central nervous system disorders, vaccination, and other uses. End users include homecare settings, hospitals, clinics, and community healthcare facilities.

The nasal sprays market consists of sales of decongestants, antihistamines, and corticosteroids. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.